SGLT2i with ARNi versus RASi in Heart Failure with Reduced Ejection Fraction: Improved Survival and Reduced Hyperkalemia Risk in a Real-World Cohort Study
{{output}}
Background: The management of heart failure with reduced ejection fraction (HFrEF) has advanced with the introduction of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and angiotensin receptor-neprilysin inhibitors (ARNi). Ho... ...
